Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SANUWAVE HealthSNWV -4.67%30 EV-to-EBIT is 3.37 as of Aug. 07, 2026. GuruFocus rates SNWV with a GF Score™ of 30/100 and a GF Value™ of $12.24 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 469 Medical Devices & Instruments companies, SANUWAVE Health ranks better than 95.52% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SANUWAVE Health's Enterprise Value for the quarter that ended in Jun. 2026 was $0.00 Mil.
SANUWAVE Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SANUWAVE Health EV-to-EBIT Related Terms
SANUWAVE Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for SANUWAVE Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, SANUWAVE Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SANUWAVE Health EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SANUWAVE Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SANUWAVE Health's EV-to-EBIT falls into.
SANUWAVE Health's current Enterprise Value is $60.57 Mil.
SANUWAVE Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SANUWAVE Health (SNWV) has a EV-to-EBIT of 3.37 as of Aug. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SANUWAVE Health and its competitors. According to the industry distribution chart, SANUWAVE Health ranks #21 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 4.5%.
Is SANUWAVE Health's EV-to-EBIT too high?
SANUWAVE Health's current EV-to-EBIT is 3.37. The Medical Devices & Instruments industry median EV-to-EBIT is 19.13. SANUWAVE Health's value of 3.37 is 82.4% below this industry median. Based on the distribution chart, SANUWAVE Health ranks #21 out of 469 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, SANUWAVE Health has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SANUWAVE Health's EV-to-EBIT compare to SRTS and COCH?
According to the Medical Devices & Instruments industry distribution chart, SANUWAVE Health ranks #21 out of 469 companies for EV-to-EBIT. This places SANUWAVE Health in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 19.13. SANUWAVE Health's value of 3.37 is 82.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.13, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SANUWAVE Health's current EV-to-EBIT of 3.37 is 82.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SANUWAVE Health and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SANUWAVE Health's current EV-to-EBIT is 3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SANUWAVE Health stock overvalued right now?
Based on GuruFocus' analysis, SANUWAVE Health (SNWV) is currently considered Possible Value Trap. The stock's GF Value™ is $12.24, compared to a current price of $5.72 — trading 53.3% below its estimated fair value. The current EV-to-EBIT is 3.37 and 82.4% below the Medical Devices & Instruments industry median of 19.13. SANUWAVE Health's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SANUWAVE Health (SNWV), the current EV-to-EBIT is 3.37 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SANUWAVE Health (SNWV) Overvalued in 2026?
Based on GuruFocus' analysis, SANUWAVE Health stock appears to be undervalued.
The current stock price of $5.72 is trading 53.3% below its estimated GF Value™ of $12.24.
GuruFocus considers SANUWAVE Health to be Possible Value Trap.
Key valuation signals for SNWV:
EV-to-EBIT: 3.37
GF Value™: $12.24 vs. price of $5.72 (53.3% below fair value)
Industry Position: 82.4% below the Medical Devices & Instruments median (#21 of 469)
No single metric tells the full story. See the SNWV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
30GF Score
Get the complete analysis for SNWV
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNWV has been successfully added to your 
